Tech Company Financing Transactions

Expansion Therapeutics Funding Round

On 9/30/2021, Expansion Therapeutics raised $80 million in Series B funding from Cormorant Asset Management, 5AM Ventures and Kleiner Perkins Caufield & Byers.

Transaction Overview

Company Name
Expansion Therapeutics
Announced On
9/30/2021
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series B
Investors

Cormorant Asset Management (Lead Investor) (Raymond Kelleher)

5AM Ventures (Scott Rocklage)

Kleiner Perkins Caufield & Byers (Beth Seidenberg)

Logos Capital

Novartis Venture Fund (Campbell Murray)

RA Capital (Andrew Levin)

Sanofi-Genzyme BioVentures (Jason Hafler)

Surveyor Capital

Westlake Village BioPartners

Proceeds Purpose
Proceeds from the financing will be used to advance the company's small molecule RNA platform (SMiRNA) to identify clinical candidates in myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and various tauopathies.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10996 Torreyana Rd. 280
San Diego, CA 92121
USA
Phone
(858) 764-4290
Website
www.expansionrx.com
Email Address
[email protected]
Overview
Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. We are initially focused on expansion repeat disorders, a set of ~30 genetic diseases for which there are no satisfactory therapies.
Profile
Expansion Therapeutics LinkedIn Company Profile
Social Media
Expansion Therapeutics Company Twitter Account
Company News
Expansion Therapeutics News
Facebook
Expansion Therapeutics on Facebook
YouTube
Expansion Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Renato Skerlj
  Renato Skerlj LinkedIn Profile  Renato Skerlj Twitter Account  Renato Skerlj News  Renato Skerlj on Facebook
Controller
Jennifer Visco
  Jennifer Visco LinkedIn Profile  Jennifer Visco Twitter Account  Jennifer Visco News  Jennifer Visco on Facebook
Founder
Matthew Disney
  Matthew Disney LinkedIn Profile  Matthew Disney Twitter Account  Matthew Disney News  Matthew Disney on Facebook
Vice President
Andrew Good
  Andrew Good LinkedIn Profile  Andrew Good Twitter Account  Andrew Good News  Andrew Good on Facebook
Vice President
Mark Ledeboer
  Mark Ledeboer LinkedIn Profile  Mark Ledeboer Twitter Account  Mark Ledeboer News  Mark Ledeboer on Facebook
VP - R & D
Valerie Cullen
  Valerie Cullen LinkedIn Profile  Valerie Cullen Twitter Account  Valerie Cullen News  Valerie Cullen on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/30/2021: Height venture capital transaction
Next: 9/30/2021: Wayspring venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.